DUBLIN–(BUSINESS WIRE)–The “Global Acute Ischemic Stroke – Pipeline Insight, 2022” clinical trials have been added to ResearchAndMarkets.com’s offering.
This “Acute Ischemic Stroke – Pipeline Insight, 2022” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines.
The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Acute Ischemic Stroke Emerging Drugs Chapters
This segment of the Acute Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Ischemic Stroke Emerging Drugs
Nelonemdaz: GNT
Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major routes of brain cell death leading to disability and death after stroke. Nelonemdaz previously showed better efficacy and a longer therapeutic time window than subtype-unselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two earlier phase I studies conducted in 165 healthy young and elderly volunteers in the US and China.
Tenecteplase: Genentech
Tenecteplase (TNKase, TNK-tPA or TNK) is a thrombolytic agent derived from the tissue plasminogen activator (tPA), that binds fibrin and converts plasminogen to plasmin. It is a 527-amino acid glycoprotein developed by replacing three amino acids at the T, N and K positions of the glycoprotein structure of tPA under genetic recombinant technology. After replacing threonine 103 with asparagine, asparagine 117 with glutamine and a tetra-alanine at amino acids 296-299, TNK is about eightfold more potent in dissolving clot, 80-fold higher resistance to plasminogen activator inhibitor-1 and 14-fold enhanced relative fibrin specificity, and with a longer half-life (20 min). Hence, TNK is administered as a single intravenous bolus. Tenecteplase has a well-characterized mechanism of action with important practical advantages in administration and superior clinical efficacy for patients with large-vessel occlusion. It is currently being evaluated in imaging-eligible, late-window acute ischemic stroke (AIS) patients.
SP-8203: Shin Poong
SP-8203, under development, is a new neuroprotective compound for acute ischemic stroke. It is a quinazoline-2, 4-dione derivative with multiple potent neuroprotective mechanisms of action including anti-inflammatory activities. Patent applications have been filed in 52 countries and granted in 44 countries. SP-8203, has proved as a first-in-class candidate which has a multiple neuroprotective effects through a variety of the stroke animal models.
Particularly, because it extends the therapeutic window when combined with tPA, more patients would have the benefit of reducing cerebral infarction and edema as well as hemorrhage and mortality. In fact, a few years following by the project outset, SP-8203 won the top 10 future pharmaceutical special projects run by the Ministry of Health and Welfare, because it was highly evaluated for its distinctiveness. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
NoNO-SC: NoNO
NoNO-SC is a subcutaneously injectable nerinetide analog for the treatment of all strokes. Autoinjector compatibility (i.e. a “stroke pen”) enables administration by any caregiver at home, en route to the hospital or upon arrival in the emergency department. Currently, the drug is in Preclinical stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
Acute Ischemic Stroke: Therapeutic Assessment
This segment of the report provides insights about the different Acute Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Acute Ischemic Stroke
There are approx. 35+ key companies which are developing the therapies for Acute Ischemic Stroke. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, GNT Pharma.
Phases
This report covers around 35+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Acute Ischemic Stroke Report Insights
- Acute Ischemic Stroke Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Acute Ischemic Stroke Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Genentech
- Supergene
- Tasly Pharmaceutical
- Pharmazz
- GNT Pharma
- NoNO
- Angde Biotech Pharmaceutical
- NuvOx Pharma
- Healios
- Acticor Biotech
- Biogen
- ZZ Biotech
- Revalesio Corporation
- Shionogi & Co., Ltd.
- AbbVie
- Pharming Group
- Bristol-Myers Squibb
- Roche
- Clinuvel Pharmaceuticals
- TrueBinding
- Shin Poong Pharmaceutical
- Lumosa Therapeutics
- NC Medical Research
- JCR Pharmaceuticals
- aptaTargets
- PT. Prodia Stem Cell Indonesia
Key Products
- Tenecteplase
- Recombinant staphylokinase
- Prourokinase recombinant
- Sovateltide
- Nelonemdaz
- Nerinetide
- Reteplase
- DDFPe
- Invimestrocel
- ACT-017
- TMS-007
- 3K3A-APC
- RNS60
- S-005151
- Elezanumab
- Conestat Alfa
- BMS-986177
- Balovaptan
- Scenesse (Afamelanotide)
- TB006
- SP-8203
- LT 3001
- NCS 01
- JTR-161
- ApTOLL
- Umbilical Cord Mesenchymal Stem Cells
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wv00wu
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900